Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026)

Alnylam Pharmaceuticals has reported Non Operating Income for 18 years, with the latest figure at -$47.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 611.18% year-over-year to -$47.0 million; the trailing twelve-month figure through Mar 2026 stood at -$327.3 million (down 93.75% YoY), and the FY2025 full-year result was -$178.4 million, up 11.01% from the prior year.
• Non Operating Income for Q1 2026 stood at -$47.0 million, up from -$187.0 million in the prior quarter.
• The five-year high for Non Operating Income was $9.2 million in Q1 2025, with the low at -$187.0 million in Q4 2025.
• Historically, Non Operating Income has averaged -$51.1 million across 5 years, with a median of -$38.1 million in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income tumbled 727.81% — and 2025, when it soared 145.61%.
• Alnylam Pharmaceuticals' Non Operating Income stood at -$2.6 million in 2022, then sank by 727.81% to -$21.3 million in 2023, then plunged by 317.23% to -$88.8 million in 2024, then tumbled by 110.58% to -$187.0 million in 2025, then jumped by 74.87% to -$47.0 million in 2026.
• The last three Non Operating Income figures came in at -$47.0 million (Q1 2026), -$187.0 million (Q4 2025), and -$74.1 million (Q3 2025), per Business Quant data.